Quantcast

Industry news that matters to you.  Learn more

Neurogenetic Pharmaceuticals Announces Studies Showing its Proprietary Compound Reduces Brain Plaques Associated with Alzheimer’s Disease

In the Sept 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer’s disease (AD) in a transgenic mouse model. The study further demonstrates that following chronic treatment with the gamma secretase modulator (GSM) compound from NGP, the mice were devoid of gastrointestinal side effects, an adverse finding commonly associated with gamma secretase inhibitors (GSIs).

Pathwork Diagnostics Partners with Leading Pharmaceutical Company to Discover Molecular Diagnostics for Cancer

Pathwork Diagnostics Inc., a molecular diagnostics company focused on oncology, today announced that it has entered into a research collaboration with Novartis. The parties intend to discover clinically meaningful biomarker signatures that can serve as the basis for diagnostics across a range of cancer types. Under the terms of the agreement, both parties have rights to develop and commercialize the diagnostic products. Financial terms were not disclosed.

CROs Join with MJFF for Parkinson’s Biomarker Research

Covance, Parexel and Epitomics are working with the Michael J Fox Foundation for Parkinson’s Research (MJFF) to develop biomarker candidates.

Initiation of the projects is part of efforts by MJFF to progress biomarker research. MJFF said there is “urgent need for an orchestrated, fieldwide strategy to drive tangible progress” in the sector and contract research organisations (CRO) have a role to play in this initiative.

TcLand Teams Up with Spanish Institute to Develop Assay for Predicting Response To TNFalpha Therapy

TcLand Expression is teaming up with the Hospital Vall d-Hebron Research Institute (HVIR) in Spain to develop a biomarker-based assay for predicting individual patients’ responses to TNFα blocker therapy for rheumatoid arthritis (RA). The collaboration agreement gives TcLand exclusive, worldwide rights to HVIR’s IP covering response-related biomarkers discovered by the Institute’s Sara Marsal, M.D., director of the Grup de Recerca de Reumatologia.

Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced a collaborative study with Almac’s Diagnostics division for the Company’s doxorubicin luteinizing hormone-releasing hormone (LHRH) targeted conjugate compound, AEZS-108, aimed at determining LHRH receptor expression through the development of a companion diagnostic tool. Selection for treatment with AEZS-108 is determined on the basis of LHRH receptor expression, currently measured immunohistochemically. In humans, LHRH receptors are expressed in ovarian, endometrial, breast, bladder, prostate and pancreatic tumors. AEZS-108 is currently in Phase 2 trials for advanced LHRH receptor positive ovarian and endometrial cancer.